MonoSol Rx and BiondVax Collaborate to Develop Oral Film Delivery of Flu Vaccine
Demonstrates Significant Advantages for Film Delivery in Vaccines
Warren, NJ (November 7, 2012) – MonoSol Rx, LLC (“MonoSol Rx”), the developer of PharmFilm® drug delivery technology, announced today that it has entered into a partnership with BiondVax, an Israeli based pharmaceutical company, to develop an oral film formulation of BiondVax’ universal flu vaccine, M-001, utilizing MonoSol Rx’s PharmFilm® delivery platform. There are significant advantages for this needle free delivery in vaccines, including ease of use, increased compliance and simplified distribution.
The collaboration will include the conduct of studies using MonoSol Rx's patent-protected PharmFilm® technology to investigate the activity and formulation of BiondVax influenza vaccine when delivered in a convenient oral film.
A. Mark Schobel, Co-President and Chief Executive Officer of MonoSol Rx, stated, "We have believed for some time in the significant advantages PharmFilm can offer in the delivery of a broad range of vaccines. We view this partnership with BiondVax as an opportunity to demonstrate the clear advantages our proprietary PharmFilm technology platform offers the vaccine industry. The oral, needle free delivery of film offers patients greater compliance and ease of use. We believe that the targeted oral, needle-free influenza vaccine enabled by the PharmFilm® platform will see increased patient acceptance, leading to a better protected population. Storage and distribution will also be enhanced by the film formulation, which is stable at room temperature, making vaccination easier for large numbers of patients across the country."
Schobel concluded, "MonoSol Rx's strong patent portfolio continues to
be validated by the U.S. Patent and Trademark Office, and we are
confident and proud of the innovation driven by our technology."
About MonoSol Rx
MonoSol Rx is a specialty pharmaceutical company leveraging its proprietary PharmFilm® technology to develop products which address the unmet needs of patients. PharmFilm® is designed to benefit patients by improving the convenience, efficacy, and compliance of new and currently marketed drugs. The Company's leadership in film drug delivery is supported by strong intellectual property, a pipeline of prescription formulations based on PharmFilm® technology, and two FDA approvals - Zuplenz®, the first approved prescription oral soluble film for the prevention of chemotherapy-induced, radiotherapy-induced, and postoperative nausea and vomiting, and Suboxone® sublingual film, the first sublingual film product for the treatment of opioid dependence. For press releases and other company information visit www.monosolrx.com.
* PharmFilm is a registered trademark of MonoSol Rx.